TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026

Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

Zhihua Ran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.